期刊文献+

培美曲塞联合顺铂对蒽环类和紫杉类药物治疗失败晚期乳腺癌的疗效观察 被引量:6

下载PDF
导出
摘要 目的观察培美曲塞联合顺铂对蒽环类和紫杉类药物治疗失败的晚期乳腺癌的效果。方法 102例经蒽环类和紫杉类药物化疗失败的晚期乳腺癌患者静脉滴注培美曲塞500mg/m2,第1天;静脉滴注顺铂25mg/m2(培美曲塞结束后至少30min才给药顺铂),第1至3天。每3周为1个周期。经过2周期化疗后评价疗效。结果 102例中,完全缓解11例,部分缓解45例,稳定32例,进展14例,有效率54.9%,疾病控制率86.3%,治疗后生活质量提高25例,生活质量稳定60例,生活质量降低17例,良好率83.3%。无1例死亡。结论培美曲塞二钠联合顺铂治疗对蒽环类和紫杉类药物治疗失败的晚期乳腺癌疗效确切,可以提高患者生活质量,值得临床推广应用。
作者 谢美强
出处 《广东医学院学报》 2012年第5期535-536,共2页 Journal of Guangdong Medical College
  • 相关文献

参考文献8

  • 1Boyle P, Ferly J. Cancer incidence and mortality in Europe 2004[J]. Annal Oncol, 2005, 16(3):481-488. 被引量:1
  • 2Parkin D M, Bray F, Ferlay J, et al. Global cancer statistics, 2002[J]. Cancer J Clin, 2005, 55(2):74-108. 被引量:1
  • 3Calvert H. An overview of folate metabdism:featurelevt to the antion and toxicities of antifolate anticancer agents[J]. Semi Oncol, 1999, 26(Suppl):3-10. 被引量:1
  • 4马飞,李树婷,孙燕.2006年培美曲塞研究新进展[J].癌症进展,2006,4(6):523-528. 被引量:16
  • 5Ma C X, Steen P, Rowland K M, et al. A phase trial of a combination of pemetrexed and gemcitabine in patients with metastatic breast cancer:an NCCTG study [J]. Ann Oncol, 2006, 17(2):226-231. 被引量:1
  • 6Martin M, Blasinska-Morawiec M, Salas J F, et al. A mul- ticenter, single-arm phase II study of pemetrexed plus doxo- rubicinadministered every 21 days in patients with advanced breast cancer [J]. Clin Breast Cancer, 2009, 9(3):155-160. 被引量:1
  • 7Garin A, Manikhas A, Biakhov M, et al. A phase Ⅱ study of pemetrexed and carboplatin in patients with locally advanced or metastatic breast cancer [J]. Breast Cancer Res Treat, 2008, 110(2):309-315. 被引量:1
  • 8张玺炜,高洪元,储冬英,赵子仪.培美曲塞联合顺铂方案治疗蒽环类及紫杉类治疗失败的晚期转移性乳腺癌的初步研究[J].中国癌症杂志,2009,19(9):697-700. 被引量:20

二级参考文献36

  • 1Boyle P,Ferlay J.Cancer incidence and mortality in Europe,2004[J].Annal Oncol,2005,16(3):481-488. 被引量:1
  • 2Kataja V,Castiglione M,on behalf of the ESMO Guidelines Working Group.Locally recurrent or metastatic breast cancer.ESMO clinical recommendations for diagnosis,treatment and follow-up[J].Annal Oncol,2008,19(2):9-11. 被引量:1
  • 3Parkin DM,Bray F,Ferlay J,et al.Global cancer statistics,2002[J].Cancer J Clin,2005,55(2):74-108. 被引量:1
  • 4Spielmann M,Marlin M,Namer M,et al.Activity of pemetrexed (ALIMTA,multitargeted antifolate,LY231514) in metastatic breast cancer patients previously treated with an anthracycline and a taxane:an interim analysis[J].Clin Breast Cancer,2001,2(1):47-51. 被引量:1
  • 5Hanauske AR,Chen V,Paoletti P,et al.Pemetrexed disodium:a novel antifolate clinically active against multiple solid tumors[J].Oncologist,2001,6(4):363-373. 被引量:1
  • 6Vogelzang N J,Ruathoven JJ,Symanowski J,et al.Phase Ⅲ study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma[J].J Clin Oncol,2003,21(14):2636-2644. 被引量:1
  • 7Hanna N,Shepherd FA,Fossella FV,et al.Randomized phase Ⅲ trial of pemetrexed versus docetaxel in patients with nonsmall cell lung cancer previously treated with chemotherapy[J].J Clin Oncol,2004,22(9):1589-1597. 被引量:1
  • 8Scagliotti GV,Parikh P,yon Pawel J,et al.Phase Ⅲ study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advancedstage non-small cell lung cancer[J].J Clin Oncol,2008,26(21):3543-3551. 被引量:1
  • 9Paridaens R,Dirix L,Dumez H,et al.Phase Ⅰ/Ⅱ pharmacokinetic study of pemetrexed and epirubiein in patients with locally advanced or metastatic breast cancer[J].Clin Breast Cancer,2007,7(11):861-866. 被引量:1
  • 10Garin A,Manikhas A,Biakhov M,et al.A phase Ⅱ study of pemetrexed and carboplatin in patients with locally advanced or metastatic breast cancer[J].Breast Cancer Res Treat,2008,110(2):309-315. 被引量:1

共引文献33

同被引文献47

  • 1徐兵河.改变乳腺癌临床实践的重要临床试验的回顾与评述[J].中国癌症杂志,2005,15(5):408-412. 被引量:22
  • 2Ma C X, Steen P, Rowland K M, et al. A phase II trial of a combination of pemetrexed and gemcitabine in patients with metastatic breast canc- er:an NCCTG study[J]. Ann Oncol,2006,17(2) :226 -231. 被引量:1
  • 3Silvestris N, D' Aprile M, Andreola G, et al. Rationale for the use of gemcitabine in breast cancer ( Review ) [ J ]. Int J Oneol, 2004,24 (2) :389 -398. 被引量:1
  • 4Kano Y,Akutsu M,Tsunoda S,et al. Schedule -dependent interactions between pemetrexed and cisplatin in human carcinoma cell lines in vitro [J]. Oncol Res,2006,16(2) :85 -95. 被引量:1
  • 5Cobleigh M A. Other options in the treatment of advanced breast cancer [J]. Semin Oncol,2011,38 Suppl 2:S11 - 16. 被引量:1
  • 6Scagliotti G V,Pafikh P,Von Pawel J,et al. Phase III study comparing cisplatin plus gemeitabine with eisplatin plus pemetrexed in chemother- apy - naive patients with advanced - stage non - small cell lung cancer [ J]. J Clin Oncol,2008,26(21 ) :3543 - 3551. 被引量:1
  • 7Llombart - Cussac A, Martin M, Harbeek N, et al. A randomized, doub- le - blind, phase II study of two doses of pemetrexed as first - line chemotherapy for advanced breast cancer[ J]. Clin Cancer Res,2007, 13(12) :3652 -3659. 被引量:1
  • 8Garin A, Manikhas A, Biakhov M, et al. A phase II study of peme- trexed and carboplatin in patients with locally advanced or metastatic breast cancer [ J ]. Breast Cancer Res Treat, 2008, 110 ( 2 ) : 309 -315. 被引量:1
  • 9Martin M,Blasinska- Morawiec M, Salas JF,et al. A multicenter, sin- gle - ann phase II study of pemetrexed plus doxorubicin administered every 21 days in patients with advanced breast cancer[ J]. Clin Breast Cancer,2009,9(3) :155 - 160. 被引量:1
  • 10Dent SF, Gertler S, Verma S, et al. A phase II study of biweekly peme- trexed and gemcitabine in patients with metastatic breast cancer [ J ]. Cancer Chemother Pharmaeol,2010,65 ( 3 ) :557 - 561. 被引量:1

引证文献6

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部